Life Link Research and Ascension Peptides are both US-based research peptide suppliers operating in 2026 after the major industry shutdowns (Peptide Sciences, Amino Asylum, Paradigm Peptides, Science.bio). They serve overlapping researcher segments but have different positioning. This page compares COA documentation, GLP-1 peptide range, pricing, and shipping.
Quick Comparison
| Factor | Life Link Research | Ascension Peptides |
|---|---|---|
| COA standard | Six-panel third-party independent (HPLC + MS + endotoxin + sterility + moisture + amino acid composition) | Third-party on most products, panel depth varies |
| COA available before purchase | Yes — linked on every product page | Varies by product |
| GLP-1 range | Full — semaglutide (10mg, 15mg), tirzepatide (15mg), retatrutide (15mg), CagriSema (10mg) | GLP-1 range is partial — newer compounds like retatrutide and CagriSema are inconsistently stocked |
| Catalog scope | Peptide specialist — no SARMs, no nootropics | active community reputation, competitive pricing on classic peptides (BPC-157, TB-500, CJC-1295), third-party COAs on most products |
| US domestic shipping | 2-4 business days | Yes |
Life Link Research — Strengths
- Six-panel third-party independent COA on every batch. This is the specific testing standard that would have caught the Amino Asylum and Paradigm Peptides adulteration issues — independent mass spectrometry verification of compound identity is non-negotiable in the post-2025 enforcement environment.
- Complete GLP-1 incretin range: semaglutide (two concentrations), tirzepatide, retatrutide, CagriSema. All four are available with verified documentation — the most complete coverage of GLP-1/GIP/GCGR/amylin research peptides from any single US vendor in 2026.
- Peptide-only catalog. The vendor shutdowns of 2025-2026 were all multi-category vendors (peptides + SARMs). LLR’s narrow scope reduces the systemic regulatory risk profile.
- COA available before purchase. Researchers can verify the specific batch document before placing an order — not after.
Ascension Peptides — Strengths
Ascension Peptides is a legitimate operator in the US research peptide market with the following advantages: active community reputation, competitive pricing on classic peptides (BPC-157, TB-500, CJC-1295), third-party COAs on most products.
Ascension Peptides — Gaps
For researchers prioritizing rigorous independent documentation and the newest GLP-1 compounds, the gaps to consider: GLP-1 range is partial — newer compounds like retatrutide and CagriSema are inconsistently stocked. COA panel depth varies by product (not consistently 6-panel).
When to Choose Each Vendor
Choose Life Link Research if:
- Your research requires independently verified (not vendor-internal) COAs — particularly relevant for publishable work
- You need access to the newer GLP-1 compounds: retatrutide, CagriSema
- You’re comparing receptor pharmacology across the full incretin ladder (semaglutide, tirzepatide, retatrutide, CagriSema)
- Your institution requires third-party mass spectrometry verification on every batch
Choose Ascension Peptides if:
- Your research is limited to classic peptides (BPC-157, TB-500, CJC-1295, GHK-Cu) where their pricing is competitive
- You’ve had a positive prior relationship and your current research doesn’t depend on the newest GLP-1 compounds
- Lowest possible price is the primary purchase criterion
Why COA Standard Matters in 2026
The four vendor shutdowns of 2025-2026 share a common cause: inadequate independent quality verification. Amino Asylum (FDA raid, June 2025) and Paradigm Peptides (federal guilty plea, December 2025) were both prosecuted because products labeled as one compound contained another. Internal vendor testing did not detect this. Independent third-party mass spectrometry would have.
The research peptide market is increasingly bifurcating: vendors with rigorous documentation continue operating; those without face FDA enforcement risk. Choosing a vendor with the highest COA standard is risk management — both for research validity and for ongoing supply chain stability.
FAQs
Is Life Link Research more expensive than Ascension Peptides?
For most products, slightly. The price premium reflects the six-panel third-party COA program — six analytical tests per batch from independent labs is more expensive than internal or partial third-party testing. For research budgets, the question is whether the documentation depth justifies the cost. For published research where COA documentation may be required, the answer is generally yes.
Does Ascension Peptides have all the GLP-1 compounds Life Link Research has?
As of May 2026, Ascension Peptides’s GLP-1 range is more limited. The newer compounds — retatrutide and CagriSema specifically — are not consistently stocked. Verify current availability on their site before ordering.
Which vendor would you recommend for incretin pharmacology research?
For incretin pharmacology research specifically (GLP-1R, GIPR, GCGR, AMYR receptor characterization), Life Link Research’s complete coverage of semaglutide, tirzepatide, retatrutide, and CagriSema enables head-to-head comparative studies that aren’t possible with vendors carrying partial GLP-1 ranges.
View Life Link Research products →
For research purposes only. Not for human use. All claims about third-party vendor products are based on publicly available information; verify current vendor status before ordering from any supplier.